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Abstract
Arsenic (+3 oxidation state) methyltransferase (As3mt) is the key enzyme in the pathway for 
methylation of inorganic arsenic (iAs). Altered As3mt expression and AS3MT polymorphism have 
been linked to changes in iAs metabolism and in susceptibility to iAs toxicity in laboratory models 
and in humans. As3mt-knockout mice have been used to study the association between iAs 
metabolism and adverse effects of iAs exposure. However, little is known about systemic changes 
in metabolism of these mice and how these changes lead to their increased susceptibility to iAs 
toxicity. Here, we compared plasma and urinary metabolomes of male and female wild-type (WT) 
and As3mt-KO (KO) C57BL6 mice and examined metabolomic shifts associated with iAs 
exposure in drinking water. Surprisingly, exposure to 1 ppm As elicited only small changes in the 
metabolite profiles of either WT or KO mice. In contrast, comparisons of KO mice with WT mice 
revealed significant differences in plasma and urinary metabolites associated with lipid 
(phosphatidylcholines, cytidine, acyl-carnitine), amino acid (hippuric acid, acetylglycine, urea), 
and carbohydrate (L-sorbose, galactonic acid, gluconic acid) metabolism. Notably, most of these 
differences were sex-specific. Sex-specific differences were also found between WT and KO mice 
in plasma triglyceride and lipoprotein cholesterol levels. Some of the differentially changed 
metabolites (phosphatidylcholines, carnosine, and sarcosine) are substrates or products of 
reactions catalyzed by other methyltransferases. These results suggest that As3mt KO alters major 
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metabolic pathways in a sex-specific manner, independent of iAs treatment, and that As3mt may 
be involved in other cellular processes beyond iAs methylation.
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Introduction
Chronic exposure to inorganic arsenic (iAs) via drinking water affects millions of people 
worldwide and is associated with an increased risk of cancer (NRC, 1999) as well as non-
cancer diseases such as neurological (Tyler and Allen, 2014) and cardiometabolic disorders, 
including cardiovascular disease (Tsuji et al., 2014) and diabetes (Maull et al., 2012). In 
spite of the abundant evidence linking iAs exposure to a variety of adverse health effects, 
questions remain about the underlying biological mechanisms. Studies using powerful omics 
technologies, including metabolomics, may help to answer these questions.
Several recent studies have used metabolomics to characterize metabolic profiles associated 
with iAs exposure. A metabolomic study carried out in the general Chinese population 
identified several potential biomarkers of iAs exposure in urine (Zhang et al., 2014). 
Similarly, our recently published metabolomic analyses of urine and plasma from residents 
of Chihuahua, Mexico found 132 metabolites that were altered in iAs-exposed individuals 
(Martin et al., 2015). Metabolomic responses to iAs exposure have also been studied in 
laboratory animals, although most studies have focused on the effect of exposure to high 
levels of iAs (Garcia-Sevillano et al., 2014a,b; Wang et al., 2014). The only other study that 
examined effects of low iAs exposure was carried out in rats (Wang et al., 2015). However, 
rats are not considered a suitable animal model because avid binding of iAs metabolites to 
rat hemoglobin generates unique kinetics and pattern of iAs metabolism that differ from 
those in humans and other mammals (Lu et al., 2004). Overall, the effects of chronic iAs 
exposure on the metabolome of humans and of rodent species commonly used in laboratory 
studies of iAs toxicity, specifically mice, remain understudied.
Results of both population and laboratory studies suggest that severity of adverse effects of 
iAs exposure is determined, in part, by efficiency of iAs metabolism (Antonelli et al., 2014; 
Tseng et al., 2009). In humans and many other species, metabolism of iAs occurs by 
subsequent enzymatic methylation of iAs to form monomethyl-As (MAs) and dimethyl-As 
(DMAs), and in some species also trimethyl-As (TMAs) metabolites (Thomas et al., 2007). 
Arsenic (+3 oxidation state) methyltransferase (AS3MT) is the primary enzyme that 
catalyzes the methylation of iAs (Thomas et al., 2007). Experimental expression of rat 
As3mt in human urothelial (UROtsa) cells that do not express the AS3MT gene enables iAs 
methylation, and silencing of AS3MT in human hepatocellular carcinoma (HepG2) cells 
reduces the cell's capacity for iAs methylation (Drobna et al., 2005; Drobna et al., 2006). 
Furthermore, knockout of As3mt in mice results in a significant decrease in the rate of 
whole-body As clearance and in the accumulation of iAs in tissues (Drobna et al., 2009). For 
this reason, As3mt-catalyzed methylation of iAs is considered a detoxification process. 
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However, we and others have shown that the methylated metabolites containing trivalent As 
(AsIII) contribute to the toxicities associated with iAs exposure (McCoy et al., 2015; 
Rehman et al., 2014; Styblo et al., 2000; Tseng, 2009; Watanabe et al., 2012). Since As3mt 
is the enzyme responsible for clearance of iAs from the body and for generation of trivalent 
methylated metabolites, As3mt-knockout (KO) cells or mice are useful models for studying 
the role of iAs metabolism in adverse effects of iAs exposure. These models can also be 
used to explore other potential functions of AS3MT. AS3MT orthologs are found in many 
living organisms, ranging from simple invertebrates to modern-day humans (Thomas et al., 
2007). The conservation of AS3MT across species and during evolution suggests that, in 
addition to detoxifying iAs, this enzyme may act on other substrates (Thomas et al., 2007) 
and could play a role in metabolic pathways essential for survival (Uthus, 1992). While 
As3mt-KO mice are viable and do not show signs of dysfunction, a metabolomic analysis 
may reveal clues about the role of AS3MT beyond iAs methylation.
The present study examined plasma and urine metabolomes in As3mt-KO C57BL6 mice and 
C57BL6 wild-type (WT) mice exposed to iAs in drinking water and in unexposed control 
mice. The main goals were: (i) to characterize the metabolic response to iAs treatment, thus 
providing additional clues about the mechanisms underlying effects of iAs exposure, (ii) to 
compare the metabolic responses of WT mice that can efficiently methylate iAs with those 
of As3mt-KO mice that have severely impaired iAs methylation capacity, and (iii) to probe 
for altered pathways that may indicate novel roles of AS3MT.
Materials and Methods
Animals and treatment
All procedures involving mice were approved by the University of North Carolina (UNC) 
Institutional Animal Care and Use Committee. Male and female C57BL6 WT mice were 
obtained from Jackson Laboratories (Bar Harbor, ME) and let to acclimatize at the UNC 
Animal Facilities for one week. These WT mice were 17 weeks (±3 days) old at the 
beginning of the study. Male and female As3mt-KO mice on a C57BL6 background 
(Drobna, et al. 2009) were bred at the UNC Animal Facilities and were 17–20 weeks old at 
the beginning of the study. All mice were housed under controlled conditions (12-h light/
dark cycle at 22+−1°C and 50±10% relative humidity) with ad libitum access to pelleted 
rodent chow (Prolab Isopro RMH 3000, LabDiet, St. Louis, MO). Mice drank either 
deionized water or deionized water containing 1 ppm As as sodium arsenite (AsNaO2, ≥99% 
pure; Sigma-Aldrich, St. Louis, MO, USA) ad libitum for four weeks (N=15–21 per 
experimental group). Water with iAsIII was freshly prepared every week to minimize 
oxidation of iAsIII to iAsV. Food and water consumption and body weight were monitored in 
all treatment groups every week and two weeks, respectively.
Urine and plasma collection
At the end of iAs-treatment, urine was collected from mice housed in metabolic cages (1 
mouse per cage) for 24 hours without access to food to avoid food contamination in urine 
samples. Urine was aliquoted and stored at −80°C until analysis. Blood from non-fasted 
mice was collected prior to sacrifice via submandibular bleeding using heparinized Caraway 
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micro-capillaries (Fisher Sc, Pittsburgh, PA). Plasma was isolated by centrifugation at 2000g 
for 10 minutes (at 4°C) and stored at −80°C until further analysis.
Analysis of iAs metabolites in urine
Hydride generation-atomic absorption spectrometry coupled with a cryotrap (HG-CT-AAS) 
was used to determine the concentration of As species, including total iAs (i.e., iAsIII + 
iAsV), total MAs (MAsIII + MAsV) and total DMAs (DMAsIII + DMAsV) (Hernandez-
Zavala et al., 2008). As previously reported, limits of detection for this method are: 0.05 ng 
As/mL for MAs or DMAs and 0.1 ng As/mL for iAs (Martin et al., 2015). The concentration 
of total speciated As in urine was calculated as sum of iAs, MAs, and DMAs. For quality 
control, a certified standard reference material Arsenic Species in Frozen Human Urine 
(SRM 2669; National Institute of Standards and Technology) was analyzed with the mouse 
urine samples. The recoveries of As from this SRM ranged from 87% for DMAs to 91% for 
iAs,
Metabolomic analysis
Numbers of plasma and urine samples used for the metabolomic analysis ranged from 13 to 
21 per experimental group (volumes collected from some mice were not sufficient for the 
analyses). Samples were prepared as previously described with some modifications (Ni et 
al., 2014; Qiu et al., 2014; Qiu et al., 2013). Briefly, the samples were extracted with cold 
organic solvents (for plasma - methanol:chloroform, 3:1; for urine - acetonitrile). The extract 
was split into two aliquots. One aliquot was used for untargeted metabolomic profiling with 
an Agilent 7890A gas chromatograph coupled to a Leco Pegasus time of flight mass 
spectrometer (GC-MS, Leco Corp., St Joseph, MI). Because previous studies in laboratory 
rodents found major effects of iAs exposure on metabolism of lipids and amino acids 
(Garcia-Sevillano et al., 2014a,b; Wang et al., 2014), we used the second aliquot for targeted 
metabolomic analysis of metabolites associated with amino acid and lipid metabolism by an 
Acquity ultra performance liquid chromatography coupled to a Xevo TQ-S mass 
spectrometer (LC-MS, Waters Corp., Milford, MA). The raw data files generated from LC-
MS and GC-MS were processed, respectively, with TargetLynx Application Manager 
(Waters Corp., Milford, MA) and ChromaTOF software (Leco Corp., St Joseph, MI), in 
order to extract peak signal (normalized by dividing metabolite peak area by total 
chromatogram area), mass spectral data, and retention times for each metabolite. The 
detected metabolites from both analytical platforms were annotated and combined using an 
automated mass spectral data processing (AMSDP) software package (Ni et al., 2012).
Metabolomic data analysis
ANOVA and hierarchical clustering analysis were conducted using Partek Genomics 
SuiteTM Software (St. Louis, MO). Data were analyzed using a three-way multi-variate 
ANCOVA model including sex, genotype, and iAs treatment as covariates. To identify 
significantly changed metabolites between groups (i.e., differentially changed metabolites), 
significance was set with a False Discovery Rate (FDR) corrected q-value of q<0.05. 
Unsupervised two-way hierarchical clustering was performed on standardized data from LC-
MS and GC-MS analysis with unknown metabolites excluded. Metabolites or animals were 
clustered using a Euclidean distance metric and average linkage. Results were displayed as a 
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heatmap representing fold-difference from the overall mean of each metabolite. To 
maximize the probability of capturing relevant metabolites for pathway analysis, a less 
stringent cutoff value of p<0.05 was used to select metabolites for pathway analysis. 
Pathways with p<0.05 using the online tool, MetaboAnalyst (Xia, 2010), were determined to 
be significant. The KEGG Pathway database was used to create a pathway map specific to 
this investigation (Kanehisa, 2000).
Plasma lipid analysis
Plasma triglycerides and cholesterol associated with high density lipoproteins (HDL) 
fraction and with a combined low density/very low density lipoprotein (LDL/VLDL) 
fraction were analyzed using commercial enzymatic assays according to manufacturer's 
instructions (Wako Diagnostics, Mountainview, CA and Abcam, Cambridge, MA, 
respectively). Data was analyzed with a full factorial three-way ANOVA analysis 
considering sex, treatment, and genotype with post hoc Student's t tests assessing relevant 
comparisons using JMP 10.1 (SAS Institute Inc, Cary, NC).
Results
Phenotypic characteristics of WT and As3mt-KO mice
The average concentrations of total speciated As in the urine of WT and As3mt-KO mice 
treated with 1 ppm As in drinking water were about 10-fold higher than in the urine of the 
corresponding controls (466 ng/ml vs. 47 ng/ml in WT, 545 ng/ml vs. 57 ng/ml in KO mice) 
(Supplemental Figure 1). Knockout of As3mt had no statistically significant effects on total 
urinary As levels within the control groups. However, in iAs-treated animals, KO mice had 
significantly higher levels of total speciated As levels in urine as compared to iAs-treated 
WT mice. No significant differences were found between male and female mice in any 
groups. The majority of total speciated As in the urine of As3mt-KO mice was represented 
by iAs: on average 58% for controls and 91% for iAs-treated mice. In contrast, iAs 
accounted for only 8 and 10% of total speciated As in urine of WT controls and iAs-treated 
mice, respectively. DMAs was the major As metabolite, representing 40% of total urinary 
As in control KO mice and 89% in control WT mice. In iAs-treated animals, DMA 
constituted 9% of total urinary As in KO mice and 92% in WT mice. Notably, treatment 
with 1 ppm As had no significant effects on body weights of either WT or As3mt-KO mice 
(Suppl. Figure 2). There were no differences in the weights of female KO and WT mice, 
regardless of treatment. However, male KO mice treated with iAs were somewhat heavier at 
sacrifice than the iAs-treated, WT males. No significant differences were found in food 
consumption (Suppl. Figure 3A). Similarly, there were no differences in the amount of water 
consumed by female WT, female KO mice and male KO mice; however, male WT mice 
drank more water than mice in any other group (Suppl. Figure 3B). Treatment with iAs had 
no effect on the amount of water consumed by either WT or KO mice.
Plasma and urine metabolites identified by metabolomics analyses
The targeted analysis using LC-MS identified 172 metabolites in plasma and 135 
metabolites in urine. Global GC-MS profiling detected an additional 76 and 98 metabolites 
in plasma and urine, respectively, and 184 plasma and 320 urinary unidentified metabolites 
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which were excluded from subsequent analyses. Thus, a total of 248 plasma and 233 urinary 
metabolites were identified (Suppl. Table 1) and used in the statistical analyses. 
Unsupervised two-way clustering analysis showed that animals with similar metabolite 
profiles clustered primarily by sex and, to a much lesser extent, by genotype or iAs treatment 
(Figure 1). Further comparisons characterized differences in the plasma and urine 
metabolomes between experimental groups differentiated by sex, genotype and treatment.
Changes in plasma and urine metabolomes associated with iAs treatment
Direct comparisons of plasma and urinary metabolite concentrations of control mice and 
iAs-treated mice revealed only minor shifts associated with iAs treatment, and only in 
plasma of female As3mt-KO mice (Table 1). All three significantly changed urine 
metabolites (two acylcarnitine species and a sphingomyelin species) were associated with 
lipid metabolism. No metabolites were found significantly changed due to iAs treatment in 
other experimental groups. However, the effect of iAs treatment can be inferred indirectly by 
comparing the number of KO-associated metabolites in iAs-treated and control mice. For 
example, 42 metabolites were changed in plasma and urine of control female KO mice when 
compared with control female WT mice; however, only 15 metabolites were found 
significantly changed in comparison of KO and WT female mice treated with 1 ppm iAs 
(Table 2, Suppl. Figure 4). Similar differences in numbers and types of KO-associated 
metabolites can be seen in male control mice when compared to male iAs-treated mice 
(Table 2, Suppl. Figure 4). These observations imply that the effect of iAs-treatment on the 
plasma and urine metabolite profiles may be greater than that indicated by direct 
comparison.
Changes in plasma and urine metabolomes associated with As3mt KO
To characterize the effect of As3mt knockout on plasma and urine metabolomes, we 
identified all plasma and urinary metabolites that were shifted in control and iAs-treated 
male and female KO mice when compared to their respective wild-type counterparts (Table 
2). From these comparisons, we selected the plasma and urinary metabolites that changed in 
both KO male and female mice, thus isolating metabolites associated with As3mt KO, 
regardless of sex. Control female KO mice had more than double the number of the KO-
associated metabolites found in male KO mice (Figure 2). In the iAs-treated groups, female 
KO mice showed half as many KO-associated metabolites as compared to males (Figure 2). 
The KO-associated metabolites common to control male and female KO mice were two 
phosphatidylcholine (PC) species (PC aa C36:0, PC aa C40:4) and cytidine, all increased in 
KO mice. Three KO-associated metabolites, all PC species, were common to iAs-treated 
male and female KO mice (PC aa C26:0, PC aa C36:5, PC ae C34:1).
KO-associated changes in urine metabolome—In comparisons of control animals, 
female KO mice had more differentially changed urinary metabolites than KO males when 
compared to respective WT mice. A total of 27 metabolites were changed in KO female 
controls but only seven metabolites had a fold change greater than 2: 2-hydroxybutyric acid, 
L-sorbose, gluconic acid, galactonic acid, cytidine, urea, and sarcosine (Table 2, Figure 3A–
C). Thirteen metabolites were changed in control KO males, including five with fold 
changes greater than 2: cytidine, acetylglycine, hippuric acid, carnosine, and one acyl-
Huang et al. Page 6
Arch Toxicol. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
carnitine species (C14:2-OH) (Table 2, Figure 3A, D–F). The highest fold changes were 
found for acetylglycine and hippuric acid, but acetylglycine decreased by 8-fold while 
hippuric acid increased by 16-fold. Similar, though not significant, changes in hippuric acid 
and acetylglycine were found in comparisons of female KO mice vs. WT mice. Cytidine was 
increased in urine of both male and female KO mice as compared to respective WT mice 
(Table 2, Figure 3A). In comparisons of iAs-treated mice, male KO mice had more 
significantly changed metabolites than KO females (15 vs. 11) when compared to the 
respective WT mice. Of the 11 changed metabolites in female KO mice, six metabolites had 
fold changes greater than 2: citrulline, aminoadipic acid, 2-hydroxybutyric acid, glutamate, 
and two PCs (PC aa C26:0 and PC ae C30:2) (Table 2). The urinary concentration of 2-
hydroxybutyric acid remained significantly decreased in female KO mice after treatment 
with iAs (Table 2). In male KO mice, seven metabolites had fold changes equal to or greater 
than two: 4-hydroxybenzoic acid, carnosine, gluconolactone, cytidine, hippuric acid, and 
two acylcarnitine species (C14:2-OH and C14:2) (Table 2). Cytidine and hippuric acid were 
still significantly increased in iAs-treated male KO mice as compared to iAs-treated male 
WT mice (Figure 3A,E) but acetylglycine levels were no longer significantly different 
(Figure 3D). Hippuric acid and acetylglycine concentrations were lower in iAs-treated as 
compared to control mice, but these differences were not statistically significant (Figure 
3E,D). The urinary levels of these two metabolites followed similar trends in female mice, 
but changes due to knockout of As3mt were not statistically significant.
KO-associated changes in plasma metabolome—Fewer metabolites were found to 
be significantly changed due to KO of As3mt in plasma than in urine. Notably, most of the 
KO-associated metabolites in plasma were PC species. The greatest number of changed PCs 
was found in the comparison of control KO and WT females; all these PCs were increased in 
plasma of KO females, although the fold-change did not exceed 1.34 (Table 2). When male 
control KO mice were compared with control WT males, two PCs were changed (one 
increased and one decreased), along with carnosine (decreased) and oxoglutaric acid 
(increased). In comparisons of iAs-treated KO and WT mice, PCs were changed (generally 
increased) in plasma of both female and male KO mice (Table 2). All 4 changed metabolites 
in plasma of females were PCs (3 increased, 1 decreased). The iAs-treated male KO mice 
had more significantly changed PCs in the plasma than iAs-treated females (6 vs. 4), as well 
as more significantly changed metabolites overall (21 vs. 4), when compared to the 
respective WT mice. The KO-associated metabolite changes in iAs-treated male mice 
included decreased levels of carnosine, spermidine, kynurenine, and various acyl-carnitine 
species, though fold-changes did not exceed 2. Plasma acyl-carnitines were changed only in 
comparison of iAs-treated male KO and WT mice.
Metabolic pathways affected by iAs treatment and As3mt knockout
Because very few metabolites were found to be changed by iAs treatment using the q<0.05 
filter (Table 1), a less stringent cutoff value of p<0.05 was used to identify significantly 
changed plasma and urinary metabolites for the analysis of affected pathways. With the less 
stringent cutoff, greater numbers of metabolites were identified as significantly changed due 
to iAs treatment (Suppl. Table 2) and due to As3mt knockout (Suppl. Table 3; Suppl. Figure 
5). Using Metaboanalyst, many pathways were identified as enriched for these differentially 
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changed metabolites; however, these pathways contained only one to three changed 
metabolites (hits) and often the same few metabolites were responsible for hits in multiple 
pathways (Supplemental Table 4). The pathways enriched as a result of iAs-treatment were 
genotype- and sex-specific. Pathways of amino acid metabolism were enriched only in iAs-
treated male and female WT mice when compared to the respective controls (Supplemental 
Table 4). In KO mice, the pathways enriched by iAs treatment were associated mainly with 
metabolism of lipids (in males) and carbohydrates (in females). Pathways of amino acid 
metabolism were also enriched in comparisons of As3mt-KO and WT mice (Supplemental 
Table 4). Enrichment of pathways associated with lipid (including PC) metabolism was 
found in control and iAs-treated KO males, but not in KO female mice. Although most 
changes in individual PC metabolites were detected in the comparison of control female KO 
mice to control WT females (Table 2), no significantly enriched pathways of PC 
metabolism, or lipid metabolism in general, were found by the pathway analysis, likely 
because the program treated the numerous PC species as one metabolite. In iAs-treated 
mice, As3mt KO was also linked to the enrichment of pathways of carbohydrate 
metabolism, but the enriched carbohydrate pathways differed between males and females. 
Additional enriched pathways associated with As3mt KO in either male or female mice 
included the pathways of glutathione, propanoate, and panthothenate and CoA metabolism 
(Supplemental Table 4).
To generate a holistic picture of the pathways affected by As3mt KO without the restrictions 
inherent to the pathway analysis program, a pathway map of metabolites differentially 
changed (q<0.05) due to As3mt KO was constructed using KEGG's mus musculus-specific 
pathway map database (Figure 4). The resulting map includes the enriched pathways 
described in Table 2, but highlights the sex-specific differences, the direction of change, and 
depicts the metabolites that are reported to form connections between the affected pathways.
Effects of iAs-treatment and As3mt KO on plasma lipid concentrations
To further probe changes in plasma lipids, particularly the PC metabolites that were 
observed across all comparisons, we measured concentrations of plasma triglycerides and of 
lipoprotein cholesterol as indirect measures of plasma lipoprotein concentrations. Average 
triglyceride concentrations were generally higher in KO mice as compared to WT mice, but 
this difference was statistically significant only in iAs-treated males (Figure 5A). The 
plasma of KO male mice contained significantly more triglycerides than plasma of KO 
females, regardless of iAs treatment, and control WT male mice had higher levels of 
triglycerides than control WT females. Treatment with iAs had no significant effects of 
triglyceride levels in either WT or KO mice. Very few statistically significant differences 
were found in the VLDL/LDL-cholesterol levels (Figure 5B). WT females had lower 
VLDL/LDL cholesterol than KO females but this difference was only significant in iAs-
treated animals. In contrast, WT males had higher VLDL/LDL-cholesterol levels than KO 
males, but only statistically significant in control males. Two-way ANOVA analysis of 
VLDL/LDL-cholesterol levels found the sex and genotype interaction to be statistically 
significant (p=0.005), thus confirming that the effect of genotype on VLDL/LDL cholesterol 
is different in males than in females. Treatment with iAs had no effect on VLDL/LDL- or 
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HDL-cholesterol in any group. HDL-cholesterol levels were higher in plasma of male as 
compared to female mice, in both WT and KO animals (Figure 5C).
Discussion
Effects of iAs treatment
We identified very few metabolites in KO and WT mice that were significantly changed due 
to iAs treatment using a direct ANOVA comparison. This result is consistent with data 
reported by Wang and associates (2015) who conducted a metabolomic study in male 
Sprague-Dawley rats exposed to 0.5, 2, or 10 ppm As in drinking water for 3 months. They 
found no or very few changes in the plasma metabolome at 0.5 and 2 ppm, but observed 
major changes in lipid, amino acid, and nucleotide metabolism at 10 ppm As. Thus, 
treatment with 1 ppm As for only 4 weeks may not be sufficient to result in metabolic 
disturbances in rats or mice. The lack of major metabolic shifts in mice exposed to 1 ppm As 
also raises questions about differences between rodents and humans in metabolism of iAs. 
Mice are thought to metabolize iAs more efficiently than humans (Vahter, 1994), and thus 
may be more resistant to iAs exposure. Our recent study in Chihuahua, Mexico showed that 
exposures to only ppb levels of As in drinking water (up to ~200 ppb) result in extensive 
metabolite shifts in human plasma and urine (Martin et al., 2015). This result may indicate 
higher susceptibility of humans to iAs toxicity and may justify application of higher doses of 
iAs in laboratory studies using mice to model iAs exposure in humans.
Effects due to As3mt KO: The role of sex
Unsupervised hierarchical clustering analysis showed that mice with similar metabolite 
profiles were clustered primarily by sex, and less by genotype or treatment (Figure 1). 
Significantly changed metabolites were different in males and females, further indicating 
that sex modifies the effect of the KO genotype on the metabolite profiles. Pathway analysis 
suggests that changes associated with knockout of As3mt were related to lipid, amino acid, 
and carbohydrate metabolism. Lipid metabolism was changed in both KO males and females 
but alterations in other pathways appeared to be largely sex specific.
Effects on lipid metabolism—Decreased levels of plasma PCs, increased triglycerides, 
increased acyl-carnitines and lyso-PCs have been previously reported in mice administered 
with 3 mg As/kg/day by gavage (Garcia-Sevillano et al., 2014a). Increased levels of acyl-
carnitines and lyso-PCs were also found in plasma of rats exposed to 10 ppm As in drinking 
water (Wang et al., 2015). Changes in the same types of lipid metabolites were also found in 
the present study, but these changes were primarily associated with As3mt KO and to a 
much lesser extent with iAs treatment.
Knockout of As3mt was associated with extensive changes in PC species and a related 
metabolite, cytidine, across all comparisons, with the most prominent changes in the 
comparison of female KO vs. female WT mice (Table 2). Biosynthesis of PCs occurs via 
two pathways: the cytidine-diphosphate (CDP) pathway and the pathway catalyzed by 
phosphatidyethanolamine N-methyltransferase (PEMT). In the CDP-pathway, CDP-choline 
is combined with diacylglycerol to form PC. The PEMT pathway involves three subsequent 
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methylations of phosphatidylethanolamine using S-adenosylmethionine (AdoMet) as a 
methyl group donor. The PEMT pathway occurs only in the liver and synthesizes ~30% of 
hepatic PCs (Sundler and Akesson, 1975). Notably, knockout of PEMT in mice has been 
shown to alter plasma lipoproteins levels in a sex-specific manner (Noga and Vance, 2003) 
and PEMT activity appears to be regulated by estrogen (Resseguie et al., 2007). Both CDP- 
and PEMT-pathways are necessary for normal production of plasma lipoproteins (Yao and 
Vance, 1988; Noga et al., 2002; Jacobs et al., 2004), specifically VLDL.
Results of the plasma triglyceride and lipoprotein cholesterol analyses performed in this 
study did not mirror the changes we observed in PC metabolites, although the higher levels 
of VLDL/LDL cholesterol in iAs-treated female KO vs. WT mice were consistent with the 
overall higher levels of plasma PCs (Table 2, Figure 5). Triglycerides in plasma of iAs-
treated male KO mice were significantly higher than in plasma of WT counterparts; this 
difference may be associated with higher body weight of the KO mice (Suppl. Figure 2) 
which appeared obese at the end of this study. Nevertheless, we found differences due to sex 
in all lipid measures. Future studies should examine mechanisms by which knockout of 
As3mt affects pathways of PC synthesis and degradation, and lipid metabolism in general, in 
a sex-specific manner.
Acyl-carnitines were also among lipid metabolites changed in response to As3mt KO, 
particularly in male mice. Acyl-carnitines facilitate transfer of fatty acids into the 
mitochondria for fatty acid oxidation (Peng et al., 2013; Reuter and Evans, 2012). The 
changes in acyl-carnitines observed in KO mice in this study could reflect changes in rate of 
fatty acid oxidation, and consequently, in energy production.
Effects on amino acid and nitrogen metabolism—A number of metabolites related 
to amino acid metabolism were changed in As3mt-KO mice, particularly in male mice 
(Table 2). Two metabolites - hippuric acid and acetylglycine - had the greatest fold changes 
in the urine of male KO mice as compared to WT mice. However, while the hippuric acid 
level increased, the level of acetylglycine decreased in As3mt-KO mice (Figure 3D,E). The 
same trends, while not statistically significant, were found in female mice. Hippuric acid and 
acetylglycine are products of the conjugation of glycine with benzoyl-CoA and acetyl-CoA, 
respectively, which is catalyzed by glycine N-acyltransferase (Dempsey et al., 2014; 
Schachter and Taggart, 1954). Degradation of dietary polyphenols by gut microorganisms is 
thought to be a major source of benzoic acid and other glycine conjugation substrates 
(Knights and Miners, 2012; Lees et al., 2013). Elimination of the gut bacteria using 
antibiotics or germ-free mice was shown to eliminate hippuric acid excretion (Lees et al., 
2013; Nicholls et al., 2003; Yap et al., 2008). As such, hippuric acid is considered a urinary 
microbial-mammalian cometabolite. Excretion of acetylglycine in urine was increased in 
mice after ingestion of alcohol, presumably due to increased formation of acetic acid 
(Manna et al., 2011). Colonic bacteria can ferment dietary fiber to form acetate, possibly 
explaining the association of acetylglycine with dietary fiber intake in humans (Cummings, 
1983; Lustgarten et al., 2014). Thus, the changes in urinary levels of hippuric acid and 
acetylglycine found in this study could be associated with influences on the microbiome, 
possibly due to As3mt KO or due to different diets used at the UNC animal facility where 
the KO mice were bred and at the Jackson lab where the WT mice were purchased.
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An almost 6-fold decrease in urea levels was found in urine of female KO, but not in urine of 
male KO mice, in comparisons with corresponding WT mice (Figure 3B). The production of 
urea in the urea cycle is the major mechanism for disposal of nitrogen during catabolism of 
amino acids. The decrease in urea production seen here in female KO mice may indicate a 
potential disruption of this mechanism in a sex-dependent manner.
Effects on energy/carbohydrate metabolism—Growing evidence suggests that iAs is 
an environmental diabetogen that impairs glucose homeostasis (Maull et al., 2012). Previous 
metabolomics studies have shown changes in carbohydrate metabolites in humans (Martin et 
al., 2015) and laboratory animals (Garcia-Sevillano et al., 2014 a,b; Wang et al., 2015) 
exposed to iAs. However, our metabolomics analysis found only minor effects of iAs 
treatment on pathways of carbohydrate metabolism, and only in KO female mice 
(Supplemental Table 4). Most of the changes in carbohydrate metabolites and metabolic 
pathways were associated with As3mt KO, and these changes were sex-specific (Table 2; 
Supplemental Table 4).
Effects on metabolites associated with methylation reactions—The inability of 
As3mt-KO mice to efficiently methylate iAs may have resulted in altered availability of 
AdoMet for other methylation reactions, thus influencing plasma or urinary levels of 
substrates and/or products of these reactions. The KO-associated increases in plasma PC 
levels may reflect higher activity of the PEMT pathway due to increased AdoMet 
availability. Currently, iAs is the only known substrate of As3mt but our metabolomic 
analyses in As3mt-KO mice could indicate other, so far unidentified, substrates. Here, we 
found that knockout of As3mt in mice affected levels of metabolites in two other 
methylation pathways: the metabolism of carnosine and sarcosine.
The concentration of carnosine was significantly decreased in the plasma and urine of both 
control and iAs-treated KO male animals as compared to corresponding WT males (Figure 
3F). Carnosine is a dipeptide of beta-alanine and L-histidine and is found at high 
concentrations in skeletal muscle and the brain (Boldyrev et al., 2013). Methylation of 
carnosine by carnosine N-methyltransferase generates anserine, a storage form of carnosine 
in tissues (Boldyrev et al., 2013; McManus, 1962; Winnick and Winnick, 1959). A decrease 
in plasma carnosine in KO males could reflect an increased formation of anserine due to 
increased AdoMet availability. The sex differences in carnosine levels in plasma of WT mice 
found in this study (Figure 3F) are consistent with previous studies showing that males have 
more carnosine in skeletal muscle than females (Baguet et al., 2012; Penafiel et al., 2004). 
Sarcosine levels were significantly higher in urine of control KO females as compared to 
control WT females, and also in urine of control KO females as compared to KO males 
(Figure 3C). Sarcosine is formed by methylation of glycine, catalyzed by glycine N-
methyltransferase (GNMT), and is also a byproduct of hydrolysis of dimethylglycine in the 
betaine homocysteine methyltransferase pathway (Luka et al., 2009). The formation of 
sarcosine by GNMT is thought to play a role in regulation of cellular methylation capacity 
(Cook et al., 1989; Horne et al., 1989; Luka et al., 2009; Mudd et al., 1980). Thus, an 
increase in sarcosine could indicate an increased availability of AdoMet in control KO mice 
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that are not able to efficiently methylate iAs in the diet. The sex-dependence and the effects 
of iAs treatment on these changes, however, require further investigation.
Conclusions
This study was the first to examine metabolomic profiles associated with knockout of As3mt 
in mice treated with iAs and in control mice. Surprisingly, we found that treatment with 1 
ppm As for four weeks elicited little or no change in the metabolite profile of both WT and 
As3mt-KO mice, males and females. This finding is consistent with results of previous 
metabolomics studies in rodents exposed to low levels of iAs, suggesting that higher 
exposure levels may be required to reproduce in mice the metabolomic changes observed in 
people exposed to iAs in the ppb range. In contrast, knockout of As3mt was associated with 
significant changes in both plasma and urine metabolomes and these changes were often 
sex-specific, implying that sex hormones may play an important role in regulation of the 
As3mt-catalyzed reactions or in systemic responses to the knockout of As3mt. Many of the 
altered metabolites were associated with lipid (specifically PC) and lipoprotein metabolism, 
carbohydrate metabolism, and amino acid metabolism. Some of the altered metabolites were 
substrates or products of AdoMet-dependent methylation reactions, suggesting that 
knockout of As3mt altered AdoMet utilization in these reactions or that As3mt may 
methylate other, As-unrelated substrates. It is unclear, why WT male mice drank more water 
than mice in any other group and whether this difference could explain some of the sex-or 
knockout-dependent differences in the urine or plasma metabolomes. However, this data 
suggest that studies comparing WT and As3mt-KO mice should monitor water consumption 
and account for possible differences in data evaluation. Future studies, using targeted, tissue-
specific metabolomics or metabolite/enzyme-specific analyses are needed to explain the KO-
associated changes in metabolite profiles observed in this study, as well as the sex-specific 
differences.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Urinary and plasma metabolites identified by metabolomic analyses: Heat maps generated 
by unsupervised two-way clustering analysis show relative levels of metabolites (columns) 
in plasma (A) and urine (B) of control (0 ppm) and iAs-treated (1 ppm) male (M) and female 
(F) wild-type (WT) and As3mt-KO (KO) mice (rows). The metabolite levels are mean 
centered with high relative levels indicated in red and low relative levels indicated in blue.
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Figure 2. 
Number of urinary and plasma metabolites significantly changed (q<0.05) in As3mt-
knockout (KO) male and female mice in comparison with wild-type (WT) counterparts. 
Venn diagrams show overlapping and sex-specific plasma and urinary metabolites of control 
(left) and iAs-treated (right) mice. The bolded numbers represent the total number of 
changed metabolites in each section of the diagram; the arrows indicate metabolites that 
increased or decreased in response to knockout of As3mt.
Huang et al. Page 17
Arch Toxicol. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. 
Relative concentrations of selected metabolites determined by GC-MS (A,B,D,E) or LC-MS 
(C, F) in urine of wild-type (WT) and As3mt-knockout (KO), male (M) and female (F) mice, 
control (0 ppm) or iAs-treated (1 ppm). Mean and SE are shown with N=13–21 per group. 
*Indicates statistically significant differences between experimental groups (q<0.05).
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Figure 4. 
Diagram of metabolic pathways involving metabolites significantly altered (q<0.05) in 
plasma or urine of control and/or iAs-treated male and female As3mt-knockout mice when 
compared to corresponding wild-type males and females. Arrows indicate a relationship 
based off KEGG pathways specific to mus musculus and may represent more than one 
enzymatic step.
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Figure 5. 
Concentrations of lipids in plasma of wild-type (WT) and As3mt-knockout (KO), male (M) 
and female (F), control (0 ppm) and iAs-treated (1 ppm) mice: A, triglycerides (N=9–19); B, 
LDL/VLDL-cholesterol (N= 8-15); C, HDL-cholesterol (N= 8-15). Data shown as mean ± 
SE. * Indicates statistically significant differences between experimental groups (p<0.05)
Huang et al. Page 20
Arch Toxicol. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Huang et al. Page 21
Table 1
Plasma and urinary metabolites found significantly changed (q<0.05) in comparisons assessing effect of iAs 
treatment in male and female wild-type (WT) and As3mt-knockout (KO) mice. Fold change indicates 
difference from the second group in the comparison.
Urine Plasma
Comparison Metabolite q-value Fold Change Metabolite q-value Fold change
KO, female 1 ppm vs 0 ppm C18:1 0.01 −1.50 none
C14 0.02 −1.36
SM (OH) C14:1 0.01 1.79
KO, male 1 ppm vs 0 ppm none none
WT, female 1 ppm vs 0 ppm none none
WT, male 1 ppm vs 0 ppm none none
*CX:Z, acyl-carnitine; SM(OH)CX:Z, sphingomyolipid (X indicates number of carbons of the fatty acid tail and Z indicates total number of double 
bonds).
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Table 2
Plasma and urinary metabolites found significantly changed (q<0.05) in comparisons of As3mt–KO (KO) and 
wild-type (WT) male and female mice. Fold change indicates difference from the second group in the 
comparison.
Urine Plasma
Comparison Metabolite q-value Fold Change Metabolite q-value Fold change
Control, female KO vs WT 
(42)*
Urea 0.03 −5.97 PC aa C38:3 <0.01 1.34
2-Hydroxybutyric acid <0.01 −2.48 PC aa C38:0 <0.01 1.29
Suberic acid 0.02 −1.81 PC aa C36:3 0.04 1.17
Adipic acid 0.01 −1.57 PC aa C42:1 0.04 1.19
Pelargonic acid 0.03 −1.45 PC ae C40:2 0.02 1.20
Glycolic acid 0.03 −1.39 PC aa C36:1 0.02 1.20
3-Methyl-2-oxovaleric acid 0.04 −1.22 PC ae C42:2 0.04 1.21
Creatinine 0.04 −1.04 PC ae C36:5 0.01 1.22
PC ae C36:5 0.04 1.21 PC aa C42:2 0.02 1.23
PC aa C36:0 0.01 1.25 PC aa C36:2 0.04 1.23
PC ae C36:3 <0.01 1.26 PC aa C40:1 0.02 1.24
PC ae C36:4 <0.01 1.28 PC aa C40:4 0.03 1.26
C18:1-OH 0.04 1.38 PC aa C40:6 0.02 1.27
C18 0.02 1.45 PC aa C38:4 0.03 1.28
D-Threitol 0.03 1.50 Valine 0.04 1.28
Ribonolactone 0.04 1.52
Myoinositol 0.02 1.60
C18:1 <0.01 1.62
L-Arabitol 0.01 1.63
1,5-Anhydrosorbitol 0.03 1.77
Adenosine 0.03 1.78
Dopamine 0.04 1.80
Cytidine 0.04 2.21
Sarcosine 0.04 2.21
Galactonic acid <0.01 3.36
Gluconic acid <0.01 3.36
L-Sorbose 0.05 4.00
Control, male KO vs WT (17)* Acetylglycine <0.01 −16.82 Carnosine 0.01 −1.49
Carnosine <0.01 −2.44 PC aa C26:0 <0.01 −1.16
C14:2-OH 0.02 −2.31 PC aa C32:1 <0.01 1.47
Aspartate <0.01 −1.96 Oxoglutaric acid 0.04 1.59
C7-DC 0.02 −1.85
Uracil 0.04 −1.64
PC aa C36:0 <0.01 1.29
PC aa C40:4 <0.01 1.58
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Urine Plasma
Comparison Metabolite q-value Fold Change Metabolite q-value Fold change
2-Hydroxy-3-methylbutyric acid <0.01 1.69
C6 (C4:1-DC) 0.01 1.69
PC aa C40:5 <0.01 1.82
Cytidine <0.01 2.74
Hippuric acid <0.01 8.51
iAs-treated, female KO vs WT 
(15)*
Citrulline 0.01 −3.58 PC aa C26:0 <0.01 −1.19
PC aa C26:0 0.02 −2.50 PC aa C38:3 0.01 1.29
Aminoadipic acid 0.01 −2.41 PC aa C36:5 0.01 1.27
2-Hydroxybutyric acid <0.01 −2.32 PC aa C36:1 <0.01 1.26
PC ae C30:2 <0.01 −2.30
Glutamate 0.02 −2.15
Ketoleucine <0.01 −1.64
PC ae C34:1 <0.01 −1.39
PC aa C38:6 <0.01 −1.33
PC ae C40:6 <0.01 −1.28
PC ae C36:4 <0.01 1.24
iAs-treated, male KO vs WT 
(36)*
C14:2-OH <0.01 −2.91 C18:1 <0.01 −1.99
4-Hydroxybenzoic acid 0.03 −2.81 C18:2 <0.01 −1.97
Carnosine <0.01 −2.25 C7-DC 0.01 −1.86
Gluconolactone 0.01 −2.01 C18 <0.01 −1.86
C14:2 0.02 −1.98 Carnosine <0.01 −1.82
Uridine 0.02 −1.90 C16 <0.01 −1.75
D-Glucuronic acid 0.04 −1.31 Spermidine <0.01 −1.70
2-Hydroxy-3-methylbutyric acid <0.01 1.45 C16:2-OH <0.01 −1.61
Adenine 0.03 1.52 C18:1-OH 0.03 −1.59
Succinic acid 0.05 1.79 Kynurenine 0.02 −1.51
O-Phosphoethanolamine 0.01 1.86 C14:2 0.01 −1.50
Glycerol 3-phosphate 0.01 1.94 C16:1-OH 0.03 −1.45
PC aa C40:5 <0.01 2.18 t4-OH-Pro <0.01 −1.42
Cytidine <0.01 2.49 Phenylalanine 0.03 −1.37
Hippuric acid 0.01 9.42 Tryptophan 0.04 −1.33
PC ae C34:1 0.02 −1.24
PC aa C26:0 <0.01 −1.14
PC aa C36:5 0.02 1.26
PC aa C40:4 0.01 1.34
PC aa C40:3 0.01 1.51
PC aa C32:1 <0.01 1.59
Phosphatidylcholine notation: PC; phosphatidylcholine, aa; two fatty acid ester linkages, ae; one ester and one ether linkage, CY:Z is a description 
of the fatty acid composition of two PC tails where Y indicates total number of carbons in both fatty acid tails and Z indicates total number of 
double bonds.
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*Numbers in parentheses indicate total number of changed metabolites in that comparison. CX; acylcarnitine where X indicates number of carbons 
of the fatty acid tail. SM; sphingomyolipid.
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